Kindbody
Kindbody runs fertility clinics and employer fertility benefits, competing with Progyny.
On the record
Checkpoint: Outcome of the $75M preferred-stock raise to existing shareholders
The call
Kindbody's survival now depends on closing a $75M insider raise before AI or Progyny even become the main story.
Kindbody helps employers and insurance companies manage fertility treatment coverage and connect patients to clinics. The company bet heavily on owning its own clinics to stand out, but this turned into a money-eating problem it cannot afford; rival Progyny makes more money by just handling the insurance paperwork and recommendations instead of running clinics. Large health insurers are now building their own fertility programs and using software robots to automate the same work Kindbody does, so even if the company survives its current cash crisis, it will compete on price and technology against much bigger players with cheaper tools.
Why
01
AI pressure: Generic AI automation of benefits claims routing and care navigation. AI can automate the benefits-navigation layer Kindbody sells, letting insurers build it in-house instead of buying Kindbody. Could AI do the core job? Yes, likely.
02
Bigger players: Progyny (NASDAQ: PGNY). Progyny runs an asset-light model with 7.2M lives and $58.5M net income while Kindbody's owned clinics burn cash and close locations. Could a giant copy it? Yes, easily.
03
What protects it. Owned clinics give Kindbody direct control of care quality, but that same asset base is now the debt anchor it can't service.
What would change this call
Outcome of the $75M preferred-stock raise by Feb/March 2026. Shows whether Kindbody secures runway or heads toward distressed sale or wind-down.
Any further clinic closures announced beyond the six already shut since 2024. Confirms whether contraction of the owned-clinic model is accelerating.
Whether a buyer like IVIRMA, Boston IVF, or a large payer announces acquisition talks. Indicates if Kindbody's equity value survives via strategic rescue rather than collapse.
Any further clinic closures announced beyond the six already shut since 2024. Confirms whether contraction of the owned-clinic model is accelerating.
Whether a buyer like IVIRMA, Boston IVF, or a large payer announces acquisition talks. Indicates if Kindbody's equity value survives via strategic rescue rather than collapse.
Key numbers
- Valuation fell from $1.8B to $400M
- 6 clinics closed since early 2024
- Progyny net income $58.5M vs Kindbody cash crisis
Named risks
- Failure to close the $75M preferred stock raise could force distressed sale or wind-down.
- Active federal litigation (American Infertility of New York v. Kindbody, filed June 2025) and pending class-action investigation over lab practices.
- Continued clinic closures and net contraction of owned-clinic footprint undermining differentiated model.
- Reputational damage from Bloomberg/iHeart investigative podcast detailing alleged clinical errors and retrieval quotas.
- Leadership churn (three CEOs in under two years) disrupting strategic execution.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Progyny | losing to | Progyny reported $1.29B revenue and 7.2M covered lives in 2025 vs Kindbody's ~3M lives as of mid-2025 |
| Carrot Fertility | losing to | Carrot covers 4M+ lives across 1,000+ clients globally as of April 2025, exceeding Kindbody's employer footprint |
| Maven Clinic | contesting | Maven competes directly in employer-sponsored fertility and family health benefits bundling as of 2026 |
| IVIRMA Global / Boston IVF | losing to | IVIRMA became world's largest fertility group after acquiring Boston IVF in 2024, a potential acquirer or rival |
| Large insurers and TPAs | losing to | Insurers/TPAs reportedly piloting in-house fertility benefits, threatening standalone carve-out vendors like Kindbody as of 2026 |
Questions people ask
- Is Kindbody profitable in 2026?
- No. Despite a mid-2024 press release claiming profitability, Bloomberg reported in September 2025 that Kindbody was in financial crisis and hemorrhaging cash, and by February 2026 it was attempting a $75M preferred stock raise while its valuation had fallen to about $400 million from a $1.8B peak.
- Is Kindbody laying off staff or closing clinics?
- Yes. Kindbody has closed six clinics since early 2024, including Los Angeles, Columbus, Miami, Philadelphia, Portland, and Southfield, per a February 23, 2026 Fertility Bridge report, while headcount fell to roughly 613-614 employees by mid-2026, down about 7% year over year.
- Who is Kindbody's biggest competitor?
- Progyny (NASDAQ: PGNY) is Kindbody's dominant rival, reporting $1.29B revenue and $58.5M net income in 2025 with about 590 employer contracts covering 7.2 million lives, dwarfing Kindbody's roughly 3 million covered lives and 113-135 employer clients as of mid-2025.
- Could AI replace Kindbody's benefits administration business?
- The benefits-administration layer (claims routing, care navigation, cost benchmarking) is exposed to automation, which is why Kindbody launched an AI-driven fertility platform on February 12, 2026, still in pilot phase with a 2027 rollout target; independent verification of its impact is not yet available.
- Who owns Kindbody?
- Kindbody is privately held and venture-backed, founded by Gina Bartasi in 2018, with investors including Perceptive Advisors, JPMorgan's Morgan Health, GV (Google Ventures), and RRE Ventures; no acquisition or public listing has occurred as of mid-2026.
- What is Kindbody's current valuation and funding status?
- Kindbody's valuation peaked at $1.8 billion in March 2023 but had reportedly fallen to as low as $400 million by February 2026, as the company pursued a $75M preferred-stock offering to existing shareholders after a prior $30-50M raise attempt failed in 2024.
Timeline
- 2026-05-28Greg Lindberg sentenced to 12 years for fraud; Kindbody's Chicago clinic tied to his baby project
- 2026-03-17Kindbody announces partnerships with wearable maker Luna and financing firm Future Family
- 2026-02-23Report: Kindbody tries to raise $75M as it shutters clinics and shuffles C-suite
- 2026-02-12Kindbody unveils AI-driven next-generation fertility platform, entering employer pilot
- 2026-02-03Angela Barrie named Chief Commercial Officer
- 2025-12-08Girard Sharp launches investigation into alleged upselling and embryo mishandling
- 2025-09-16Bloomberg and iHeartPodcasts launch investigative podcast 'IVF Disrupted: The Kindbody Story'
- 2025-09-01Bloomberg reports Kindbody in financial crisis, hemorrhaging cash per internal documents
- 2025-06-10David Stern, ex-CEO of Boston IVF, named Kindbody CEO
- 2023-03-02Kindbody raises $100M led by Perceptive Advisors, reaching $1.8B peak valuation
Revision history
22 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Our New Funding and Reinventing Fertility Healthcare (2023-03-02)
- Kindbody Continues Nationwide Expansion (2024-03-19)
- Kindbody Tries to Raise $75M As It Shutters Clinics, Shuffles C-Suite (2026-02-23)
- Female founders had a record year. But a wave of 'zombie unicorns' is looming (2026-03-24)
- Kindbody revenue, valuation & funding
- Fertility Pioneer and Kindbody Founder Gina Bartasi Returns as CEO (2024-06-11)
- Kindbody Names David Stern as CEO (2025-06-10)
- Kindbody Reviews (2026-06-07)
- Kindbody - Headcount, Funding & Open Jobs (2026-07-02)
- Kindbody Appoints Angela Barrie as CCO (2026-02-03)
- Kindbody Unveils Next-Generation Fertility Platform (2026-02-12)
- Luna and Kindbody Partner (2026-03-17)